Panion's emission is finalised and the dog safety study is progressing well
Panion's shares emission that was running from 16-30 May and raised appr. 5.2 MSEK before emission costs, has now been completed and all payments processed.
The CEO and three members of the management had signed up for buying shares in Panion in this emission, and this was finalized well for CEO Anja Holm and board member Lars Friis Mikkelsen. However, for board member Dede Willis and Director of Business development Carlos N Velez, the American banks could not handle the requested transactions via AktieTorget, and these two subscriptions had to be cancelled. Instead the shares are sold to Swedish investors.
"This is very unfortunate, because we certainly would have liked to include these two leading profiles on the list of shareholders", says CEO Anja Holm, "but we appreciate all the effort that was put into finding solutions for a very complex situation."
Panion is currently running a safety study in dogs with the innovative product candidate GC01-canine in cooperation with the University of Copenhagen under the lead of associate professor David Woldbye, Department of Neuroscience.
"The study is progressing well, and the animal phase is so far without negative or unforeseen events for all dogs in the study. We are very pleased with the development and look forward to finalizing the animal phase according to plan, so we can report the results to the market as soon as possible" says CEO Anja Holm. "The coming steps in the development plan is a pilot clinical study in client-owned dogs, which have drug-resistant epilepsy".
JULY 31 2018
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.
Panion develops a gene therapy treatment for dogs with epilepsy. The clinical trial in dogs with real epilepsy will take place in the large investigator clinic, Long Island Veterinary Specialists (LIVS) in New York, USA. The study procedures are advancing well in accordance with the plan. The vector material is produced and undergoing testing procedures.
Panion is attracting interest from the agribusiness intelligence and animal health media Animal Pharm, where journalist Sian Lazell yesterday, 31.st of January 2019, noted the news on financing of the development program from Panion: https://bit.ly/2t1tgeK "Panion secures extra funding to back R&D. The financing round was carried out through the issuance of notes with warrants attached to Yorkville Advisors Global, that have a principal amount of SEK 100,000 each.
Panion Animal Health AB ("Panion") kallar på en andra tranche från den investeringsfond som förvaltas av Yorkville Advisors Global ("Yorkville").
Panion Animal Health AB ("Panion") draws down a second tranche from the investment fund managed by Yorkville Advisors Global ("Yorkville").
Panion Animal Health AB
Marknadsplats: Spotlight Stock Market
2019-04-25 Årsredovisning 2018